Drug Patent List
Oppositions
Newsletter
Weekly Digest

Pharsight

Caspofungin Acetate Patent Expiration

Caspofungin Acetate was first introduced by Merck And Co Inc in its drug Cancidas on Jan 26, 2001. Another drug containing Caspofungin Acetate is Caspofungin Acetate. 8 different companies have introduced drugs containing Caspofungin Acetate.


Caspofungin Acetate Patents

Given below is the list of patents protecting Caspofungin Acetate, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Cancidas US5378804 Aza cyclohexapeptide compounds Mar 16, 2013

(Expired)

 Merck
Cancidas US5378804

(Pediatric)

 Aza cyclohexapeptide compounds Sep 16, 2013

(Expired)

 Merck
Cancidas US5514650 Aza cyclohexapeptide compounds Jan 26, 2015

(Expired)

 Merck
Cancidas US5514650

(Pediatric)

 Aza cyclohexapeptide compounds Jul 26, 2015

(Expired)

 Merck
Cancidas US5792746 Aza cyclohexapeptide compounds Mar 16, 2013

(Expired)

 Merck
Cancidas US5792746

(Pediatric)

 Aza cyclohexapeptide compounds Sep 16, 2013

(Expired)

 Merck
Cancidas US5952300 Antifungal compositions Mar 28, 2017

(Expired)

 Merck
Cancidas US5952300

(Pediatric)

 Antifungal compositions Sep 28, 2017

(Expired)

 Merck
Cancidas US6136783 Antifungal compositions Mar 28, 2017

(Expired)

 Merck
Cancidas US6136783

(Pediatric)

 Antifungal compositions Sep 28, 2017

(Expired)

 Merck
Caspofungin Acetate US9636407 Caspofungin acetate formulations Dec 21, 2032 Fresenius Kabi Usa


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Caspofungin Acetate's patents.

Given below is the list recent legal activities going on the following patents of Caspofungin Acetate.

Event Date Patent/Publication
Patent litigations
Payment of Maintenance Fee, 4th Year, Large Entity 02 Nov, 2020 US9636407
Recordation of Patent Grant Mailed 02 May, 2017 US9636407
Patent Issue Date Used in PTA Calculation 02 May, 2017 US9636407
Email Notification 13 Apr, 2017 US9636407
Issue Notification Mailed 12 Apr, 2017 US9636407
Dispatch to FDC 29 Mar, 2017 US9636407
Application Is Considered Ready for Issue 28 Mar, 2017 US9636407
Issue Fee Payment Verified 27 Mar, 2017 US9636407
Issue Fee Payment Received 27 Mar, 2017 US9636407
Mail PUBS Letter Withdrawing a Notice Requiring Inventors Oath or Declaration 15 Mar, 2017 US9636407



Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳

Caspofungin Acetate Generics

Several generic applications have been filed for Caspofungin Acetate. The first generic version for Caspofungin Acetate was by Gland Pharma Ltd and was approved on Sep 29, 2017. And the latest generic version is by Areva Pharmaceuticals Inc and was approved on Oct 1, 2021.

Given below is the list of companies who have filed for Caspofungin Acetate generic.


1. XELLIA PHARMS APS

Xellia Pharmaceuticals Aps has filed for 2 different strengths of generic version for Caspofungin Acetate. Given below are the details of the strengths of this generic introduced by Xellia Pharms Aps.

Strength Dosage Form Availability Application Pathway TE code Launch Date
70MG/VIAL powder Discontinued INTRAVENOUS N/A Jul 2, 2018
50MG/VIAL powder Discontinued INTRAVENOUS N/A Jul 2, 2018


2. AREVA PHARMS

Areva Pharmaceuticals Inc has filed for 2 different strengths of generic version for Caspofungin Acetate. Given below are the details of the strengths of this generic introduced by Areva Pharms.

Strength Dosage Form Availability Application Pathway TE code Launch Date
50MG/VIAL powder Prescription INTRAVENOUS AP Oct 1, 2021
70MG/VIAL powder Prescription INTRAVENOUS AP Oct 1, 2021


3. CIPLA

Cipla Ltd has filed for 2 different strengths of generic version for Caspofungin Acetate. Given below are the details of the strengths of this generic introduced by Cipla.

Strength Dosage Form Availability Application Pathway TE code Launch Date
50MG/VIAL powder Discontinued INTRAVENOUS N/A Jul 12, 2018
70MG/VIAL powder Discontinued INTRAVENOUS N/A Jul 12, 2018


4. NORVIUM BIOSCIENCE

Norvium Bioscience Llc has filed for 2 different strengths of generic version for Caspofungin Acetate. Given below are the details of the strengths of this generic introduced by Norvium Bioscience.

Strength Dosage Form Availability Application Pathway TE code Launch Date
50MG/VIAL powder Discontinued INTRAVENOUS N/A Sep 29, 2017
70MG/VIAL powder Discontinued INTRAVENOUS N/A Sep 29, 2017


5. HENGRUI PHARMA

Jiangsu Hengrui Pharmaceuticals Co Ltd has filed for 2 different strengths of generic version for Caspofungin Acetate. Given below are the details of the strengths of this generic introduced by Hengrui Pharma.

Strength Dosage Form Availability Application Pathway TE code Launch Date
50MG/VIAL powder Prescription INTRAVENOUS AP Jun 28, 2018
70MG/VIAL powder Prescription INTRAVENOUS AP Jun 28, 2018


6. GLAND

Gland Pharma Ltd has filed for 2 different strengths of generic version for Caspofungin Acetate. Given below are the details of the strengths of this generic introduced by Gland.

Strength Dosage Form Availability Application Pathway TE code Launch Date
50MG/VIAL powder Prescription INTRAVENOUS AP Sep 29, 2017
70MG/VIAL powder Prescription INTRAVENOUS AP Sep 29, 2017